Mazabraud Yann 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
RYTM EVP Yann Mazabraud Receives 23,350 RSU Award
What Happened
Yann Mazabraud, EVP and Head of International at Rhythm Pharmaceuticals (RYTM), received a grant of 23,350 restricted stock units (RSUs) on February 11, 2026. The RSUs were granted at $0.00 (typical for compensation awards) and represent contingent rights to receive one share of common stock per RSU when vested.
Key Details
- Transaction date: 2026-02-11; filing date (Form 4): 2026-02-13 (filed within the normal 2-business-day window).
- Award: 23,350 RSUs, acquisition price reported as $0.00 (derivative award).
- Vesting (per footnote): 25% of the RSUs vest on each of March 1, 2027; Feb 1, 2028; Feb 1, 2029; and Feb 1, 2030. RSUs have no expiration date.
- Footnote F1: each RSU = right to one share upon vesting.
- Shares owned after the transaction: not disclosed in the provided filing excerpt.
Context
This was a compensation grant (an award), not an open-market purchase or sale — such awards are common for executives and are meant to align long-term incentives. Because these are RSUs, no shares are issued until vesting conditions are met; they therefore do not indicate an immediate buying or selling signal.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-02-11+23,350→ 23,350 total→ Common Stock (23,350 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The restricted stock units vest as to 25% of the total shares on each of March 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.